Corcept Therapeutics is a pharmaceutical company which discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome. The Company is also developing Korlym in different combinations to treat patients with triple-negative breast cancer and metastatic castration-resistant prostate cancer. In addition, it develops product candidates for the treatment of Cushing's syndrome and solid-tumor cancers.
Net income (Q1, 2018)
EBIT (Q1, 2018)
Market capitalization (21-May-2018)
Closing share price (21-May-2018)